ASMB · Assembly Biosciences, Inc.

Summary

Assembly Biosciences, Inc. reported financial results for the year ended December 31, 2025, with collaboration revenue of $72.3 million, net loss of $6.1 million or $0.55 per share, and cash, cash equivalents, and marketable securities of $248.1 million projected to fund operations into 2028. Highlights include licensing its helicase-primase inhibitor program to Gilead for a net $35 million option fee.

Key takeaways

• materiality
• HIGH
• extracted_facts